Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B

Rheumatology

Volumn 47, Issue 12, 2008, Pages 1838-1840

  Nagashima, T ^a   Minota, S ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATLIZUMAB; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ENTECAVIR; HEPATITIS B(E) ANTIGEN; PREDNISOLONE; VIRUS DNA;

ABSENCE OF SIDE EFFECTS; ADULT; AMINOTRANSFERASE BLOOD LEVEL; CASE REPORT; COLONOSCOPY; DISEASE ASSOCIATION; DRUG SAFETY; ECHOGRAPHY; ENDEMIC DISEASE; FEMALE; GENETIC SCREENING; HEPATITIS B; HUMAN; IMMUNE RESPONSE; LETTER; LIVER FUNCTION TEST; LONG TERM CARE; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SEROLOGY; TREATMENT DURATION; VIRUS LOAD;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MIDDLE AGED;

EID: 56649094588     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken384     Document Type: Letter

References (10)

1. Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65:983-9.
2. Maini RN, Taylor PC, Szechinski J et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006;54:2817-29.
3. Anelli MG, Torres DD, Manno C et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. Arthritis Rheum 2005;52:2519-20.
4. Flowers MA, Heathcote J, Wanless IR et al. Fulminant hepatitis as a consequence of reactivation of hepatitis B virus infection after discontinuation of low-dose methotrexate therapy. Ann Intern Med 1990;112:381-2.
5. McMahon BJ. Epidemiology and natural history of hepatitis B. Semin Liver Dis 2005;25(Suppl. 1):3-8.
6. Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology 2006;43:S173-81.
7. Nishimoto N, Kishimoto T. Interleukin 6: From bench to bedside. Nat Clin Pract Rheumatol 2006;2:619-26.
8. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. New Engl J Med 2004;350:1118-29.
9. Kakumu S, Shinagawa T, Ishikawa T et al. Serum interleukin 6 levels in patients with chronic hepatitis B. Am J Gastroenterol 1991;86:1804-8.
10. Ogawa J, Harigai M, Akashi T et al. Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody. Ann Rheum Dis 2006;65:1667-9.